Muscular Dystrophy Pipeline Report 2015 - 21 Companies & 47 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/89rk9v/muscular) has announced the addition of the "Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - aTyr Pharma, Inc. - Benitec Biopharma Limited - Bioblast Pharma Ltd. - BioMarin Pharmaceutical Inc. - Evotec AG - F. Hoffmann-La Roche Ltd. - Fate Therapeutics, Inc. - Genethon - Genzyme Corporation - Isis Pharmaceuticals, Inc. - Marina Biotech, Inc. - Novogen Limited - PolyNovo Limited - Prothelia, Inc. - SanBio, Inc. - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Valentia Biopharma S.L. For more information visit http://www.researchandmarkets.com/research/89rk9v/muscular
FATE: 7.25 (unch), BMRN: 141.67 (+1.54), ISIS: 53.50 (+0.42), SRPT: 30.02 (+0.66), XLRN: 30.03 (+0.20)
Dry (Atrophic) Macular Degeneration Therapeutics Pipeline Review, H1 2015 - 20 Companies & 29 Drug Profiles
M2 - Thu Jul 09, 9:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d36tg9/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Bioheart, Inc. - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Eleven Biotherapeutics Inc. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AdipoCell - APL-2 - avacincaptad pegol sodium - EBI-028 - eculizumab - emixustat hydrochloride - fluocinolone acetonide - Gene Therapy for Ocular Diseases - GS-020 - GSK-933776 - HMR-59 - ICR-14967 - lampalizumab - MA09-hRPE - MC-1101 - methotrexate - minocycline Gel - NM-9405 - NT-501 - OpRegen - OpRegen Plus - RC-1 Alpha - Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - RST-001 - Small Molecules for Age Related Macular Degeneration - Small Molecules for AMD - Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - TT-231 For more information visit http://www.researchandmarkets.com/research/d3...y_atrophic
OCAT: 5.22 (+0.14), OPHT: 53.92 (+0.84), FOMX: 11.18 (+0.22), GSK: 42.45 (+0.65), ALIM: 4.56 (+0.15), ALXN: 192.53 (+4.37)
Benitec Acquires Full Rights To Hepatitis B Program
PR Newswire - Thu Jul 09, 6:15AM CDT
Benitec Biopharma (ASX: BLT; OTCPK: BTEBD) and China-based Biomics Biotechnologies are pleased to announce Benitec has acquired the full rights to the pre-clinical ddRNAi-based Hepatitis B (HBV) therapeutic program, Hepbarna(TM), which was previously under development as a joint venture between the two companies.
Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT
BLUE: 159.03 (+0.60), DRNA: 12.61 (+0.31), ALNY: 121.77 (+5.73), TKMR: 11.71 (+0.46), JUNO: 52.05 (+1.72), CELG: 118.84 (+1.97)
PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis of the 20 Leading Biotech Companies
M2 - Thu Jul 02, 5:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfrgdp/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis" company profile to their offering. "PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis" report is an essential source of information and analysis on the gene therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends analysis, The publisher provides an in-depth analysis of the current and future growth drivers of the gene therapy market. The report discusses the key factors shaping and driving the gene therapy business, and provides insights on the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of gene therapies. Key Questions Answered - What are the drivers of the gene therapy field? - Who are the leading companies involved in the development of gene therapies? - What are the major trends in gene therapy clinical trials? - What specific therapeutic areas and indications are receiving the most clinical research? - What progress has been made in terms of viral vector technology and gene delivery? - What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)? - Has investor confidence been restored in the gene therapy field? Scope - This report provides market developments across the gene therapy field, including clinical trials, deals, and pipeline investments - Investment examined on both the industry and financial communities - Broad discussion on the science behind gene therapies, viral vectors, and gene delivery - Clinical trials activity examined across phase of development, therapy area, and indication. - This report offers a deep dive into the synergies behind partnering and acquisition activity - Deals activity examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action - Pipeline profiles of 20 leading biotech companies developing gene therapies Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Gene Therapy Overview 4 Market Developments 5 Clinical Trials 6 Company Analysis 7 Deals Landscape 8 Strategic Outlook 9 Appendix Companies Mentioned - Advantagene - ALS Therapy Development Institute - Amarna Therapeutics - American Gene Technologies - AnGes MG - Applied Genetic Technologies International - Asklepios BioPharmaceutical - Avalanche Biotechnologies - Benitec BioPharma - Bluebird bio - Celladon - Cellectis - CFR Pharmaceuticals - Chiesi Farmaceutici - Dimension Therapeutics - GeneCure Biotechnologies - Genethon - GenSight Biologics - InoCard - Oxford BioMedica - Proximagen - ReGenX Biosciences - Sangamo BioSciences - Spark Therapeutics - Tacere Therapeutics - TransgeneTransposagen - UniQure - Voyager Therapeutics For more information visit http://www.researchandmarkets.com/research/rf...armasphere
ONCE: 60.80 (+1.43), SGMO: 9.86 (-0.02), AAVL: 16.25 (+0.62)
Biotech Investors Should Read Bibliographies Of Chief Scientific Officers
Intrepid Investor - at Seeking Alpha - Tue Jun 30, 11:42AM CDT
BLUE: 159.03 (+0.60), BIIB: 388.23 (-11.06), TBIO: 1.37 (-0.02), SGMO: 9.86 (-0.02), SRNE: 17.09 (+0.39), CELG: 118.84 (+1.97), VICL: 0.70 (unch), GILD: 113.74 (+0.38), SGEN: 47.09 (+0.57), AEZS: 0.24 (+0.01), REGN: 526.01 (+16.98)
Benitec Biopharma Limited - Product Pipeline Review - 2014
M2 - Tue Jun 09, 7:54AM CDT
Product Pipeline Review - 2014
Benitec Biopharma Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial
PR Newswire - Wed Apr 29, 6:05AM CDT
Benitec Biopharma (ASX: BLT; OTCPK: BTEBY), a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit. The fifth patient is the third and final patient to be dosed in Cohort 2.
Asklepios Executes License with Benitec
Business Wire - Thu Apr 16, 12:34PM CDT
Benitec Biopharma and Asklepios BioPharmaceutical, Inc. (AskBio) have announced entering into a broad license agreement, granting Benitec rights to AskBio's proprietary platform gene therapy technologies. AskBio's Adeno-Associated Virus (AAV) gene therapy technologies are currently being used in Benitec's phase I/II first-in-man trial, to evaluate the safety and efficacy of its experimental therapy (TT-034), for the treatment of Hepatitis C (HCV). HCV is the most common chronic blood-borne infection in the United States, and is the leading cause of chronic liver disease, end-stage cirrhosis, and liver cancer.
Benitec Provides Update On TT-034 Trial
PR Newswire - Tue Apr 07, 6:11AM CDT
Benitec Biopharma (ASX:BLT; OTCPK:BTEBY), a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that laboratory results from liver biopsies in the company's 'first in man', Phase I/IIa clinical trial of TT-034 for hepatitis C confirmed that the trial is proceeding according to expectations.
Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial
PR Newswire - Wed Mar 11, 6:00AM CDT
Benitec Biopharma (ASX: BLT; OTCPK: BTEBY), a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. This is the second patient to be dosed in Cohort Two, with the third and final patient in Cohort Two well advanced in their preparation for dosing.
Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Mon Jan 19, 4:31PM CST
The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dys...eport.html .
FATE: 7.25 (unch), ISIS: 53.50 (+0.42), SRPT: 30.02 (+0.66)
Benitec Announces Publication Of Independent Research Supporting Tribetarna(TM) For Additional Cancer Indications
PR Newswire - Thu Jan 08, 7:00AM CST
Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) is pleased to advise that two peer-reviewed scientific papers were published recently that expand the range of cancers that express significant levels of beta III-tubulin, the gene targeted and silenced by Benitec's Tribetarna(TM) therapeutic. Researchers from the University of New South Wales (UNSW) in Sydney and the University Medical Center in Hamburg, Germany, independently published findings that associate the presence of beta III-tubulin with pancreatic cancer and renal cell cancer, respectively. Though preliminary, these new findings further support beta III-tubulin as an important target for difficult-to-treat cancers, and potentially open the door for Benitec to pursue additional indications with Tribetarna(TM) beyond its current development for non-small cell lung cancer.
Benitec Advances Hepatitis C Clinical Trial
PR Newswire - Wed Jan 07, 6:29AM CST
Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) is pleased to advise that the third patient in its Phase I/IIa clinical trial of TT-034 for hepatitis C was dosed earlier today at the Duke Clinical Research Unit (USA). This is a significant step for this "first in man" study, and follows review of the collective data from the first two patients by the independent Data Safety Monitoring Board (DSMB). The DSMB determined that the patients from the first dosing cohort were clear of any significant treatment-related adverse events.
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 8.64 (+0.15), ACRX: 4.20 (+0.02), EGLT: 12.42 (+0.36), AMGN: 154.10 (+2.79), NKTR: 11.40 (+0.22)
Hepatitis B - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjfhp6/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis B - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abivax - AiCuris - Akshaya Bio - Alnylam - AlphaMab - AltraVax - Amarna Therapeutics B.V. - Arrowhead Research - Assembly Biosciences - Beijing Minhai Biotechnology - Benitec Biopharma Limited - Big DNA - BioDiem - Biological E. Limited - BioStar - Bolder Biotechnology - Bukwang Pharm - CEL-SCI - Celltrion - Chiasma - Chimerix - Chongqing Zhifei Biological Products. - ChronTech Pharma - Colby Pharmaceutical Company - Dynavax Technologies - F. Hoffmann-La Roche - GeneCure LLC - Genexine - Gilead Sciences - GlaxoSmithKline - GlobalAcorn - Green Cross - HEC Pharm. - Humabs BioMed - Ildong Pharmaceutical. - Immune Targeting Systems (ITS) - Immunovaccine - Inbiopro Solutions - Indian Immunologicals Limited - Isis - Johnson & Johnson - Leukocare - LG Life Sciences - Ligand - Mologen - Mucosis B.V. - NeuroVive Pharmaceutical - Novira Therapeutics - Panacea Biotec Limited - PharmaEssentia - REPLICor - RFS Pharma - Romark Laboratories - Sanofi Pasteur - Scynexis - Seek - Sinovac Biotech - SK Chemicals. - SomaGenics - Spring Bank - TCM Biotech - Tekmira - TetraLogic - Therametrics holding - THERAVECTYS - Transgene - Uni-Bio Science Group - Vaxart - Vaxine Pty - VLP Biotech - WaterStone For more information visit http://www.researchandmarkets.com/research/pj...epatitis_b
DVAX: 28.11 (+1.67), JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38), ASMB: 18.55 (+0.67), GSK: 42.45 (+0.65), SVA: 5.26 (+0.02)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 8.64 (+0.15), PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), AXN: 1.39 (+0.16), SRNE: 17.09 (+0.39), NKTR: 11.40 (+0.22), EGLT: 12.42 (+0.36), AZN: 66.45 (+1.90), VBAY: ()
Global RNA Based Therapeutics Market 2014-2020: Market to Grow at CAGR of 28% and Reach $1.2 Billion in 2020
M2 - Wed Oct 22, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4cwd5m/global_rna_based) has announced the addition of the "Global RNA Based Therapeutics Market (Technology, Application, End Users and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The RNA Based Therapeutics Market would reach $1.2 billion by 2020 registering a CAGR of 28.4% during 2014 - 2020 Due to its ability to render targeted solutions for chronic diseases such as cancer, AIDS, rare genetic disorders, and certain cardiovascular conditions, RNA based therapeutics is expected to significantly impact the global pharmaceutical industry. The large scale funding from public and private sector, growing interest of pharmaceuticals and biotech giants for developing novel delivery technology, and anticipated saving in healthcare expenditure are propelling the growth of RNA therapeutics market. Moreover, the platform technologies such as RNAi and antisense have enabled researchers to accelerate their research activities by defining gene sequences for chronic diseases. Companies have widened the research focus on RNA based drug as well, which has fueled the growth of the overall RNA therapeutics market.Pharmaceutical companies have identified the RNA therapeutics for variety of chronic diseases and are also exploring the potential of RNA technology for diagnostic purposes. The RNA based therapeutics market, in the near future is likely to witness a substantial level of momentum due to government funding and programs aimed at commercialization of these drugs. The government of United States, through its National Institute of Health (NIH), provides funds for RNA therapeutics research, thus assist in propelling the growth of this market. To boost the research activities the U.S. FDA is providing fast track designation to the RNA products, which are in the pipeline. The study suggests that the enabled technologies such as RNA interference technology (RNAi) and RNA antisense technology will dominate the market with RNAi technology getting interest from most of the participants. The development pipeline suggests that oncology segment will emerge as the largest application segment. This is largely due to the high prevalence of such diseases and limited efficiency of available therapeutics in treating such diseases. Scope of the Report MARKET BY TECHNOLOGY - Enabling technologies - Microarrays - Labeling - Purification - Linear amplification - qRT-PCR - Inhibition - Enabled technologies - RNA Interference (RNAi) technologies - Small interfering RNA (siRNA) - MicroRNA (miRNA) - RNA antisense technologies MARKET BY APPLICATION - Cardiovascular - Kidney Diseases - Oncology - Infectious diseases - Metabolic disorders - Others MARKET BY END USERS - Research - Therapeutics - Diagnosis Companies Mentioned - Alnylam Pharmaceuticals - Benitec Biopharma Limited (Australia) - Cenix BioScience GmbH (Germany) - Dicerna Pharmaceuticals - Genzyme Corporation (USA) (A Sanofi Company) - Quark Pharmaceuticals - Silence Therapeutics PLC (UK) - Sirnaomics - Tekmira Pharmaceuticals Corp. (Canada) For more information visit http://www.researchandmarkets.com/research/4c..._rna_based
DRNA: 12.61 (+0.31), TKMR: 11.71 (+0.46)
Regen BioPharma Completes Preclinical Experiments for dCellVax Breast Cancer Immune Therapy
Marketwire - Wed Oct 01, 12:46PM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today completion of its preclinical experiments supporting the use of dCellVax, a personalized breast cancer immunotherapy. Animal studies, which have been previously published in peer-reviewed journals (1, 2), demonstrated that dCellVax is effective at stimulating the immune system of animals to kill tumors. In order to apply these findings to humans, proof of concept in human cells was needed.